Nabil Adra

19PUBLICATIONS

134CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicinePharmaceutical delivery technologies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (19)

Sort by Publication Date:

|May 14, 2026

How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

|Feb 18, 2026

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr

|Sep 24, 2025

Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Rebecca Hassoun, Reuben Ben-David, John P Sfakianos

|Mar 27, 2025

A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.

Roberto Pili, David I Quinn, Nabil Adra

|Feb 06, 2025

Prediction Model for Brain Metastasis in Patients With Metastatic Germ-Cell Tumors.

Tareq Salous, Ryan Ashkar, Sandra K Althouse

|Oct 17, 2024

SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.

Young Kwang Chae, Megan Othus, Sandip Pravin Patel

Pageof 4

Frequent Collaborators

Clint Cary

Isamu Tachibana

Siamak Daneshmand

Tanya Dorff

Aditya Bagrodia

Matthew B Rettig

Jennifer M King

Scott Eggener

Neeraj Agarwal

Jens Bedke

Frequent Collaborators

Clint Cary

Isamu Tachibana

Siamak Daneshmand

Tanya Dorff